ProCE Banner Activity


Community Care Team Workshops: New Frontline Strategies Challenge Longtime Standards in DLBCL

Watch this on-demand webcast capturing a dynamic workshop led by an expert on multidisciplinary management of patients with DLBCL in the frontline setting, including incorporating novel treatment paradigms into the standard of care.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Nurses: 1.00 Nursing contact hour

Released: September 13, 2022

Expiration: September 12, 2023

No longer available for credit.



Jeremy S. Abramson

Jeremy S. Abramson, MD, MMSc

Director, Hagler Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MA

John M. Burke

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by an educational grant from

Genentech, a member of the Roche Group

Target Audience

This program is intended for hematologists, oncologists, nurses, pharmacists, and other healthcare professionals involved in the treatment of patients with DLBCL.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Recognize the longstanding unmet medical need and rationale for novel therapies for patients with DLBCL
  • Evaluate the potential impact of the risk of disease progression for patients with DLBCL, including the economic and societal burden of failed frontline therapy
  • Plan treatment for individual patients with DLBCL, considering available data and expert recommendations


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Jeremy S. Abramson, MD, MMSc

Director, Hagler Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Jeremy S. Abramson, MD, MMSc: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Bristol-Myers Squibb/Celgene, Bluebird Bio, Century, Epizyme, Genentech, Genmab, Incyte, Kite Pharma, Kymera, Lilly, MorphoSys, Mustang Bio, Ono Pharma, Regeneron.

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

John M. Burke, MD: consultant/advisor: AbbVie, Adaptive Biotechnologies, AstraZeneca, Bayer, Bristol-Myers Squibb, Epizyme, Kymera, Kura, Lilly, MorphoSys, Novartis, Roche/Genentech, Seattle Genetics, BeiGene, TG Therapeutics, Verastem; fees for non-CME/CE services: BeiGene, Seattle Genetics.

Staff Disclosure


Jerfiz Constanzo, PhD, MBA

Scientific Director

Jerfiz D. Constanzo, PhD, MBA, has no relevant conflicts of interest to report.

Kayla Douglas, PharmD

Director of Pharmacy
Mississippi Center for Advanced Medicine
Madison, Mississippi

Kristi Kay Orbaugh, RN, MSN, RNP, AOCN, has no relevant conflicts of interest to report.

Jason J. Everly, PharmD

Jason J. Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom, has no relevant conflicts of interest to report.

Instructions for Credit


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-223-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 13, 2022, through September 12, 2023:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


The goal of this program is to improve patient care by increasing healthcare professional knowledge, competence, and performance in applying new and emerging data on frontline treatment strategies in DLBCL.